Darryl Kato

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

John O. Link, James G. Taylor, Lianhong Xu et al. · Journal of Medicinal Chemistry · 2013 · 292 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Enantioselective Synthesis of (+)-Cephalostatin 1

Kevin C. Fortner, Darryl Kato, Yoshiki Tanaka et al. · Journal of the American Chemical Society · 2009 · 136 citations · Full text

Natural Sciences, Chemistry, Medicinal Chemistry +14

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®

James G. Taylor, Sheila Zipfel, Kyla Ramey et al. · Bioorganic & Medicinal Chemistry Letters · 2019 · 88 citations

Pharmacy, Infectious Diseases, Medicinal Chemistry +9

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent

Hyock Joo Kwon, Weimei Xing, Katie Chan et al. · PLoS ONE · 2015 · 50 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®

John O. Link, James G. Taylor, Alejandra Trejo‐Martin et al. · Bioorganic & Medicinal Chemistry Letters · 2019 · 31 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12